One in Five Pfizer Drug Users Experience COVID-19 Rebound: Study

Many Paxlovid recipients have suffered from renewed symptoms.

A pedestrian walks by Pfizer's New York City headquarters in a file photograph. Jeenah Moon/Getty Images

About 20 percent of Paxlovid recipients suffer from COVID-19 rebound, according to a new study.

Of those taking Pfizer’s drug, also known as nirmatrelvir, 20.8 percent suffered virologic rebound, researchers said. That was compared with just 1.8 people who took no COVID-19 treatment.